- Home
- CCEC vs NTLA Comparison
CCEC vs NTLA Comparison
Compare CCEC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEC
- NTLA
- Stock Information
- Founded
- CCEC 2007
- NTLA 2014
- Country
- CCEC Greece
- NTLA United States
- Employees
- CCEC N/A
- NTLA N/A
- Industry
- CCEC Marine Transportation
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CCEC Consumer Discretionary
- NTLA Health Care
- Exchange
- CCEC Nasdaq
- NTLA Nasdaq
- Market Cap
- CCEC 1.4B
- NTLA 1.2B
- IPO Year
- CCEC 2007
- NTLA 2016
- Fundamental
- Price
- CCEC $21.59
- NTLA $10.52
- Analyst Decision
- CCEC Buy
- NTLA Buy
- Analyst Count
- CCEC 2
- NTLA 20
- Target Price
- CCEC $24.00
- NTLA $32.30
- AVG Volume (30 Days)
- CCEC 27.0K
- NTLA 4.6M
- Earning Date
- CCEC 07-31-2025
- NTLA 08-07-2025
- Dividend Yield
- CCEC 5.68%
- NTLA N/A
- EPS Growth
- CCEC 62.73
- NTLA N/A
- EPS
- CCEC 4.04
- NTLA N/A
- Revenue
- CCEC $424,701,000.00
- NTLA $52,857,000.00
- Revenue This Year
- CCEC $19.03
- NTLA N/A
- Revenue Next Year
- CCEC $13.94
- NTLA N/A
- P/E Ratio
- CCEC $12.52
- NTLA N/A
- Revenue Growth
- CCEC 84.28
- NTLA 14.99
- 52 Week Low
- CCEC $14.09
- NTLA $5.90
- 52 Week High
- CCEC $24.83
- NTLA $24.16
- Technical
- Relative Strength Index (RSI)
- CCEC 44.98
- NTLA 43.71
- Support Level
- CCEC $20.76
- NTLA $9.82
- Resistance Level
- CCEC $22.36
- NTLA $11.51
- Average True Range (ATR)
- CCEC 1.04
- NTLA 0.57
- MACD
- CCEC -0.09
- NTLA -0.17
- Stochastic Oscillator
- CCEC 27.13
- NTLA 30.70
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.